Details of the Drug

General Information of Drug (ID: DM26E4B)

Drug Name
Moexipril
Synonyms
Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 498.6
Logarithm of the Partition Coefficient (xlogp) 1.2
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Clearance
The clearance of drug is 441 mL/min []
Half-life
The concentration or amount of drug in body reduced by one-half in 1 hour [2]
Metabolism
The drug is metabolized via the liver []
Unbound Fraction
The unbound fraction of drug in plasma is 0.12% [2]
Vd
The volume of distribution (Vd) of drug is 183 L []
Chemical Identifiers
Formula
C27H34N2O7
IUPAC Name
(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
Canonical SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
InChIKey
UWWDHYUMIORJTA-HSQYWUDLSA-N
Cross-matching ID
PubChem CID
91270
ChEBI ID
CHEBI:6960
CAS Number
103775-10-6
DrugBank ID
DB00691
TTD ID
D00HDU
VARIDT ID
DR00006
ACDINA ID
D00443

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [4]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Peptide transporter 2 (SLC15A2) DTP PEPT2 8.33E-02 -3.63E-02 -1.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Moexipril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Moexipril and Eprosartan. Hypertension [BA00-BA04] [5]
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Moexipril and Aliskiren. Hypertension [BA00-BA04] [6]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Moexipril and TAK-491. Hypertension [BA00-BA04] [5]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Moexipril and Indapamide. Hypertension [BA00-BA04] [7]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Moexipril and Trichlormethiazide. Hypertension [BA00-BA04] [7]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Moexipril and Telmisartan. Hypertension [BA00-BA04] [5]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Moexipril and Irbesartan. Hypertension [BA00-BA04] [8]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Moexipril and Hydrochlorothiazide. Hypertension [BA00-BA04] [7]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Moexipril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [9]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Moexipril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [10]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Moexipril and Repaglinide. Acute diabete complication [5A2Y] [11]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Moexipril and Glibenclamide. Acute diabete complication [5A2Y] [11]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Moexipril and Tolazamide. Acute diabete complication [5A2Y] [11]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Moexipril and Nateglinide. Acute diabete complication [5A2Y] [11]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Moexipril and Insulin-aspart. Acute diabete complication [5A2Y] [12]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Moexipril and Glipizide. Acute diabete complication [5A2Y] [11]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Moexipril and Isosorbide dinitrate. Anal fissure/fistula [DB50] [13]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [14]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Moexipril and Cariprazine. Bipolar disorder [6A60] [15]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Moexipril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [16]
Mannitol DMSCDY9 Moderate Additive hypotensive effects by the combination of Moexipril and Mannitol. Bronchiectasis [CA24] [7]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Moexipril and Olopatadine. Conjunctiva disorder [9A60] [17]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Moexipril and Drospirenone. Contraceptive management [QA21] [18]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Moexipril and Ardeparin. Coronary thrombosis [BA43] [5]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Moexipril and Selegiline. Depression [6A70-6A7Z] [19]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Moexipril and Isocarboxazid. Depression [6A70-6A7Z] [19]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Moexipril and Tranylcypromine. Depression [6A70-6A7Z] [19]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Moexipril and OPC-34712. Depression [6A70-6A7Z] [15]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Moexipril and Phenelzine. Depression [6A70-6A7Z] [19]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Moexipril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [10]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Cannabidiol. Epileptic encephalopathy [8A62] [20]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Moexipril and Phenoxybenzamine. Essential hypertension [BA00] [21]
Acetazolamide DM1AF5U Moderate Additive hypotensive effects by the combination of Moexipril and Acetazolamide. Glaucoma [9C61] [7]
Methazolamide DM7J2TA Moderate Additive hypotensive effects by the combination of Moexipril and Methazolamide. Glaucoma [9C61] [7]
Dichlorphenamide DMH7IDQ Moderate Additive hypotensive effects by the combination of Moexipril and Dichlorphenamide. Glaucoma [9C61] [22]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Moexipril and Eplerenone. Heart failure [BD10-BD1Z] [23]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Moexipril and Chlorothiazide. Heart failure [BD10-BD1Z] [7]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Moexipril and Furosemide. Heart failure [BD10-BD1Z] [7]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Moexipril and Bumetanide. Heart failure [BD10-BD1Z] [7]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Moexipril and Hydroflumethiazide. Heart failure [BD10-BD1Z] [7]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Moexipril and Procarbazine. Hodgkin lymphoma [2B30] [19]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [24]
Didanosine DMI2QPE Minor Decreased absorption of Moexipril due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [10]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Moexipril and Isosorbide mononitrate. Hydrocephalus [8D64] [13]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Moexipril and Mipomersen. Hyper-lipoproteinaemia [5C80] [25]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Moexipril and Teriflunomide. Hyper-lipoproteinaemia [5C80] [26]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Moexipril and BMS-201038. Hyper-lipoproteinaemia [5C80] [27]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Moexipril and Potassium chloride. Hypo-kalaemia [5C77] [28]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Moexipril and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [29]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Moexipril and Propiomazine. Insomnia [7A00-7A0Z] [15]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Moexipril and ITI-007. Insomnia [7A00-7A0Z] [15]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [30]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Idelalisib. Mature B-cell leukaemia [2A82] [31]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Moexipril due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [26]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Moexipril and Ozanimod. Multiple sclerosis [8A40] [19]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Moexipril and Promethazine. Nausea/vomiting [MD90] [15]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Moexipril and Polythiazide. Oedema [MG29] [7]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Moexipril and Safinamide. Parkinsonism [8A00] [19]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Moexipril and Rasagiline. Parkinsonism [8A00] [19]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Moexipril and Terazosin. Prostate hyperplasia [GA90] [21]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Moexipril and Silodosin. Prostate hyperplasia [GA90] [21]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Moexipril and Levomepromazine. Psychotic disorder [6A20-6A25] [15]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Moexipril and Leflunomide. Rheumatoid arthritis [FA20] [26]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Moexipril and Quetiapine. Schizophrenia [6A20] [15]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Moexipril and Mesoridazine. Schizophrenia [6A20] [15]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Moexipril and Aripiprazole. Schizophrenia [6A20] [15]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Moexipril and Iloperidone. Schizophrenia [6A20] [15]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Moexipril and Paliperidone. Schizophrenia [6A20] [15]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Moexipril and Perphenazine. Schizophrenia [6A20] [15]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Moexipril and Molindone. Schizophrenia [6A20] [15]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Moexipril and Thiothixene. Schizophrenia [6A20] [15]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Moexipril and Trifluoperazine. Schizophrenia [6A20] [15]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Moexipril and Risperidone. Schizophrenia [6A20] [15]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Moexipril and Amisulpride. Schizophrenia [6A20] [15]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Moexipril and Asenapine. Schizophrenia [6A20] [15]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [20]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Moexipril and Naltrexone. Substance abuse [6C40] [32]
Tacrolimus DMZ7XNQ Moderate Increased risk of hyperkalemia by the combination of Moexipril and Tacrolimus. Transplant rejection [NE84] [33]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Moexipril and Tolbutamide. Type 2 diabetes mellitus [5A11] [11]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Moexipril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [11]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Moexipril and Insulin degludec. Type-1/2 diabete [5A10-5A11] [11]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Moexipril and Methdilazine. Vasomotor/allergic rhinitis [CA08] [15]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Moexipril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [34]
⏷ Show the Full List of 75 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Zinc stearate E00209 11178 lubricant
Haematite red E00236 14833 Colorant
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Moexipril Hydrochloride 7.5mg tablet 7.5mg Tablet Oral
Moexipril 15 mg tablet 15 mg Oral Tablet Oral
Moexipril 7.5 mg tablet 7.5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6571).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
4 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
5 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
6 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
7 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
8 Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
9 Cerner Multum, Inc. "Australian Product Information.".
10 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
11 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
12 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
13 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
14 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
15 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
16 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
17 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
18 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
19 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
22 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
23 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
24 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
25 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
26 Canadian Pharmacists Association.
27 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
28 Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
29 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
30 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
31 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
32 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
33 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
34 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.